Aerosol delivery of antimicrobial agents during mechanical ventilation: Current practice and perspectives

Current Drug Delivery

Volumn 8, Issue 2, 2011, Pages 208-212

  Michalopoulos, Argyris ^a,b   Metaxas, Eugenios I ^b   Falagas, Matthew E ^b,c  

^a HENRY DUNANT HOSPITAL   (Greece)

^b ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotics; Delivery system; Inhalation; Nebulization; Ventilation

Indexed keywords

ANTIINFECTIVE AGENT; AZTREONAM LYSINE; COLISTIN; PENTAMIDINE; TOBRAMYCIN;

AEROSOL; AEROSOL DRUG DELIVERY; ARTICLE; ARTIFICIAL VENTILATION; CRITICALLY ILL PATIENT; CYSTIC FIBROSIS; DEVICE; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; INTUBATION; JET NEBULIZER; MEDICAL NEBULIZER; METERED DOSE INHALER; MOBILIZATION; OFF LABEL DRUG USE; POWDER INHALER; PRESSURIZED METERED DOSE INHALER; PRIORITY JOURNAL; RESPIRATORY SYSTEM; TRACHEOTOMY; ULTRASONIC NEBULIZER; VIBRATING MESH APERTURE PLATE NEBULIZER;

ADMINISTRATION, INHALATION; AEROSOLS; ANTI-INFECTIVE AGENTS; CRITICAL CARE; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HUMANS; METERED DOSE INHALERS; NEBULIZERS AND VAPORIZERS; PNEUMONIA, VENTILATOR-ASSOCIATED; RESPIRATION, ARTIFICIAL;

EID: 79551627449     PISSN: 15672018     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720111794479880     Document Type: Article

References (42)

1. Falagas, M.E.; Kasiakou, S.K. Local administration of polymyxins into the respiratory tract for the prevention and treatment of pulmo-nary infections in patients without cystic fibrosis. Infection, 2007, 35(1), 3-10.
2. Kuhn, R.J. Formulation of aerosolized therapeutics. Chest, 2001, 120(3 Suppl), 94S-98S.
3. Falagas, M.E.; Siempos, I.I.; Bliziotis, I.A.; Michalopoulos, A. Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia: a meta-analysis of comparative trials. Crit. Care, 2006, 10(4), R123.
4. FDA. Colistimethate. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforP%atientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm084285.h%tm.
5. EMEA. Public summary of positive opinion for orphan designation of colistimethate sodium for the treatment of Pseudomonas aeruginosa lung infection (including colonization) in cystic fibrosis. http://www.emea.europa.eu/pdfs/human/comp/opinion/007502en.pdf.
6. Novartis. TOBI Package Insert. http://www.pharma.us.novartis.com/product/pi/pdf/tobi.pdf.
7. Falagas, M.E.; Kasiakou, S.K.; Tsiodras, S.; Michalopoulos, A. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin. Med. Res., 2006, 4(2), 138-146.
8. Geller, D.E. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir. Care, 2005, 50(10), 1313-1321.
9. Smaldone, G.C.; Palmer, L.B. Aerosolized antibiotics: current and future. Respir. Care, 2000, 45(6), 667-675.
10. Duarte, A.G.; Fink, J.B.; Dhand, R. Inhalation therapy during mechanical ventilation. Respir. Care Clin. N. Am., 2001, 7(2), 233-260.
11. Dhand, R. Aerosol delivery during mechanical ventilation: from basic techniques to new devices. J. Aerosol. Med. Pulm. Drug Deliv., 2008, 21(1), 45-60.
12. Di Paolo, E.R.; Pannatier, A.; Cotting, J. In vitro evaluation of bronchodilator drug delivery by jet nebulization during pediatric mechanical ventilation. Pediat. Crit. Care Med., 2005, 6(4), 462-469.
13. Vecellio, L.; Guerin, C.; Grimbert, D.; De Monte, M.; Diot, P. In vitro study and semiempirical model for aerosol delivery control during mechanical ventilation. Intensive Care Med., 2005, 31(6), 871-876.
14. Weber, A.; Morlin, G.; Cohen, M.; Williams-Warren, J.; Ramsey, B.; Smith, A. Effect of nebulizer type and antibiotic concentration on device performance. Pediat. Pulmonol., 1997, 23(4), 249-260.
15. Asmus, M.J.; Milavetz, G.; Tice, A.L.; Teresi M.E. In vitro characteristics of tobramycin aerosol from ultrasonic and jet nebulizers. Pharmacother., 2001, 21 (5), 534-539.
16. Newman, S.P.; Pellow, P.G.; Clarkem S.W. In vitro comparison of DeVilbiss jet and ultrasonic nebulizers. Chest, 1987, 92 (6), 991-994.
17. Eisenberg, J.; Pepe, M.; Williams-Warren, J.; Vasiliev, M.; Mont-gomery, A.B.; Smith, A.L.; Ramsey, B.W. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group. Chest, 1997, 111(4), 955-962.
18. Hess, D.; Fisher, D.; Williams, P.; Pooler, S.; Kacmarek, R.M. Medication nebulizer performance: effects of diluent volume, nebulizer flow, and nebulizer brand. Chest, 1996, 110 (2), 498-505.
19. Palmer, L.B.; Smaldone, G.C.; Simon, S.R.; O'Riordan, T.G.; Cuccia A. Aerosolized antibiotics in mechanically ventilated patients: delivery and response. Crit. Care Med., 1998, 26(1), 31-39.
20. Kesser, K.C.; Geller, D.E. New aerosol delivery devices for cystic fibrosis. Respir. Care, 2009, 54(6), 754-768.
21. Dhand, R. Basic techniques for aerosol delivery during mechanical ventilation. Respir. Care, 2004, 49(6), 611-622.
22. Schultsz, C.; Meester, H.H.; Kranenburg, A.M.; Savelkoul, P.H.; Boeijen-Donkers, L.E.; Kaiser, A.M.; de Bree, R.; Snow, G.B., Vandenbroucke-Grauls, C.J., Ultra-sonic nebulizers as a potential source of methicillin-resistant Staphylococcus aureus causing an out-break in a university tertiary care hospital. J. Hosp. Infect., 2003, 55(4), 269-275.
23. Prober, C.G.; Walson, P.D.; Jones, J. Technical report: precautions regarding the use of aerosolized antibiotics. Committee on infectious diseases and committee on drugs. Pediatics, 2000, 106(6), E89.
24. O'Malley, C.A. Infection control in cystic fibrosis: cohorting, cross contamination, and the respiratory therapist. Respir. Care, 2009, 54(5), 641-655.
25. Selting, K.; Waldrep, J.C.; Reinero, C.; Branson, K.; Gustafson, D.; Kim, D.Y.; Henry, C.; Owen, N.; Madsen, R.; Dhand, R. Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the AeroProbe intracorporeal nebulization catheter. J. Aerosol. Med. Pulm. Drug Deliv., 2008, 21(3), 255-268.
26. Gaspar, M.M.; Gobbo, O., Ehrhardt, C. Generation of liposome aerosols with the Aeroneb Pro and the AeroProbe nebulizers. J. Liposome Res., 2010, 20(1), 55-61.
27. Michalopoulos, A.; Fotakis, D.; Virtzili, S.; Vletsas, C.; Raftopou-lou, S.; Mastora, Z.; Falagas, M.E. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir. Med., 2008, 102(3), 407-412.
28. O'Riordan, T.G. Inhaled antimicrobial therapy: from cystic fibrosis to the flu. Respir. Care, 2000, 45(7), 836-845.
29. Coates, A.L. Guiding aerosol deposition in the lung. N. Engl. J. Med., 2008, 358, 304-305.
30. Wood, G.C.; Boucher, B.A. Aerosolized antimicrobial therapy in acutely ill patients. Pharmacother., 2000, 20(2), 166-181.
31. Clay, M.M.; Pavia, D.; Newman, S.P.; Clark, S.W. Factors influencing the size distribution of aerosols from jet nebulizers. Thorax 1983, 38 (10), 755-759.
32. Laube, B.L.; Jashnani, R.; Dalby, R.N.; Zeitlin, P.L. Targeting aerosol deposition in patients with cystic fibrosis: effects of alteration in particle size and inspiratory flow rate. Chest, 2000, 118 (4), 1069-1076.
33. Smaldone, G.C.; Fuhrer, J.; Steigbigel, R.T.; McPeck, M. Factors determining pulmonary deposition of aerosolized pentamidine in patients with human immunodeficiency virus infection. Am. Rev. Respir. Dis., 1991, 143 (4 Pt 1), 727-737.
34. Newman, S.P. Aerosol generators and delivery systems. Respir. Care, 1991, 36 (9), 939-951.
35. Knoch, M.; Keller, M. The customised electronic nebuliser: a new category of liquid aerosol drug delivery systems. Expert Opin. Drug Deliv., 2005, 2 (2), 377-390.
36. Flume, P.; Klepser, M.E. The rationale for aerosolized antibiotics. Pharmacother., 2002, 22(3 pt 2), S71-79.
37. Wood, G.C.; Swanson, J.M. Aerosolised antibacterials for the prevention and treatment of hospital-acquired pneumonia. Drugs, 2007, 67(6), 903-914.
38. Davis, S.S., Hardy, J.G., Newman, S.P., Wilding, I.R. Gamma scintigraphy in the evaluation of pharmaceutical dosage forms (review). Eur. J. Nucl. Med., 1992, 19(11), 971-986.
39. Geller, D.E.; Konstan, M.W.; Smith, J.; Noonberg, S.B.; Conrad, C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediat. Pulmonol., 2007, 42 (4), 307-313.
40. Panidis, D.; Markantonis, S.L.; Boutzouka, E.; Karatzas, S.; Baltopoulos, G. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest, 2005, 128(2), 545-552.
41. Klastersky, J.; Carpentier-Meunier, F.; Kahan-Coppens, L.; Thys, J.P. Endotracheally administered antibiotics for gram-negative bronchopneumonia. Chest, 1979, 75(5), 586-591.
42. Lenoir, G.; Antypkin, Y.G.; Miano, A.; Moretti, P.; Zanda, M.; Varoli, G.; Monici Preti, P.A.; Aryayev, N.L. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramy-cin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Paediatr. Drugs, 2007, 9 (Suppl 1), 11-20.